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A  79-year-old  woman  undergoing  medical  treatment  with  solifenacin  and  clenbuterol  for urinary  incon-
tinence  was  admitted  to our hospital  because  of recurrent  syncope.  Her  syncope  appeared  one  month
after  the  doses  of clenbuterol  were  increased.  Torsade  de  pointes  (TdP)  was  evident  on her  Holter  electro-
cardiogram  at the  time  when  she  developed  syncope.  Ultimately,  a  cardioverter-deﬁbrillator  with  dual
chamber  pacing  capability  was  implanted.  To  our  knowledge,  this  is  the  ﬁrst  report  of TdP  associatedorsade de pointes
T  prolongation
olifenacin
lenbuterol
mplantable cardioverter-deﬁbrillator
with  the  combination  of  solifenacin  and  clenbuterol  for urinary  incontinence.
<Learning objective:  Urinary  incontinence  increases  with  age.  Muscarinic  receptor  antagonists  are  con-
sidered  the mainstay  of  pharmacologic  treatment  for this  condition.  Some  patients  might  be  treated
with  a combination  of  a bladder  selective  muscarinic  receptor  antagonist  solifenacin  and  a  long-acting
2  adrenergic  agonist  clenbuterol.  However,  this  combination  therapy  may  cause  torsade  de  pointes  with
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syncope.>
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Torsade de pointes (TdP) occurs in several clinical settings
uch as drug treatment and inherited abnormalities of cardiac ion
hannels and can be fatal. This condition is associated with ven-
ricular action potential prolongation, which can be recognized
on-invasively on the electrocardiogram (ECG) by QT interval pro-
ongation. TdP may  be caused by some non-cardiac drugs [1–3] as
ell as antiarrhythmic drugs [4]. Not only do drugs differ in their
otential to cause TdP, but also there are several other risk factors
or drug-induced TdP such as female sex, hypokalemia, hypomag-
esemia, bradycardia, simultaneous administration of metabolic
nhibitors, and genetic factors [1,5–7]. Here, we  report a rare case
f TdP that appeared to be caused by the combination of solifenacin
nd clenbuterol to treat urinary incontinence.
ase reportA 79-year-old woman was admitted to our hospital because
f recurrent syncope. She had been treated for two years with
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5 mg/day solifenacin in combination with 20 g/day clenbuterol
for urinary incontinence. One year before admission, the dose of
solifenacin was increased to 10 mg/day, and one month before
admission, the dose of clenbuterol was increased to 40 g/day.
After an increase in solifenacin dose from 5 to 10 mg/day, QTc
interval slightly increased from 419 ms  to 428 ms.  After an addi-
tional increase in clenbuterol dose from 20 to 40 g/day, more QTc
prolongation was  observed from 428 ms  to 442 ms.  Thereafter, she
developed recurrent syncope. At the time of admission, her 12-lead
ECG showed no P waves and a regular atrioventricular junctional
rhythm with QTc 442 ms  (Fig. 1). Serum levels of electrolytes and
hepatic function were normal, but her creatinine clearance was
slightly decreased. The echocardiogram showed no structural heart
disease. After hospitalization, the ECG monitor showed frequent
premature ventricular contractions (PVCs) with short runs. TdP
was evident on the Holter ECG at the time she developed syncope
(Fig. 2). Just before the occurrence of TdP, the T wave was biphasic in
shape with prolonged QTc interval to 560 ms (Fig. 2). We  believed
that the increase in the dose of solifenacin and clenbuterol was
the cause of TdP. Therefore, we  discontinued these two medica-
tions and prescribed amiodarone (100 mg;  12 h apart) for the ﬁrst
24 h. Thereafter, the ECG monitor showed a decrease in the fre-
quency of PVCs. Her heart rate decreased to 40/min, and to prevent
more QTc prolongation, amioradone was discontinued. QTc interval
decreased to 438 ms  after withdrawing these drugs. She was at high
risk for sudden death, therefore, a cardioverter-deﬁbrillator with
vier Ltd. All rights reserved.
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(Fig. 1. The 12-lead electrocardiogram at the time of admission showed no P waves
ual chamber pacing capability was implanted. After the implan-
ation of a cardioverter-deﬁbrillator with dual chamber pacing
apability, she was free from syncope.iscussion
Solifenacin, a bladder-selective antimuscarinic drug, is widely
sed for the treatment of urinary incontinence [8]. Solifenacin has
ig. 2. The Holter electrocardiogram showed torsade de pointes (TdP), at this time, she sud
ust  before the occurrence of TdP was observed: TdP is induced by the short-long cardiac
PVC). The initiating PVC appears after the T-wave peak of the last beat before the onset o regular atrioventricular junctional rhythm with slight QTc prolongation (442 ms).
not been shown to have severe adverse cardiac effects, although
another antimuscarinic agent, telodiline, has been reported to
cause QT prolongation and TdP [2,3,8]. However, Asajima et al.
[9] reported a case of solifenacin-induced TdP associated with
QT prolongation. The case was an 81-year-old woman who was
on 5 mg/day solifenacin when TdP appeared. Clenbuterol, a long-
acting 2-adrenergic agonist, is also used for the treatment of
urinary incontinence. Clenbuterol also has not been reported to
denly developed syncope for a few seconds. A short-long-short pattern of R–R cycles
 cycles followed by an initiating short-coupled premature ventricular contraction
f TdP.
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ave severe cardiac adverse effects except for supraventricular
achycardia and atrial ﬁbrillation in a body builder who  took an
cute overdose [10].
The  combination of solifenacin and clenbuterol is often used
or the treatment of urinary incontinence. In our case, syn-
ope appeared after the doses of solifenacin and clenbuterol
ere increased from 5 to 10 mg/day and from 20 to 40 g/day,
espectively. Based on previous reports, solifenacin rather than
lenbuterol might have been the drug responsible for TdP asso-
iated with QT prolongation. However, a drug–drug interaction is
lso an important issue that should be considered. The metabolism
f solifenacin occurs via CYP3A4 [8], so its combination with other
gents that potentially inhibit CYP3A4 could increase solifenacin
evels resulting in adverse effects. However, clenbuterol is not a
YP3A4 inhibitor. Furthermore, no structural heart disease was
resent, serum electrolytes levels such as potassium and magne-
ium and hepatic function were normal, and age and mild renal
ysfunction had no clinically relevant effects on the pharmacoki-
etics of solifenacin. Therefore, we speculate that the combination
f solifenacin with clenbuterol had an impact on the development
f TdP, although the exact mechanism is unknown.
In our case, amiodarone was effective in preventing TdP.
owever, amiodarone induced bradycardia and might cause QTc
rolongation with increasing the risk of TdP, so we  were obliged to
iscontinue amiodarone. After the implantation of a cardioverter-
eﬁbrillator with dual chamber pacing capability, she was  free
rom syncope. Although we did not investigate genetic factors and
lasma drug concentrations in this case, these approaches would
e a sound strategy to evaluate the potential adverse effects of her
rug therapy.
To  our knowledge, this is the ﬁrst report of TdP associated with
he combination of solifenacin and clenbuterol for urinary inconti-
ence.
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